Adjuvant chemotherapy and relative survival of patients with stage II colon cancer - A EURECCA international comparison between the Netherlands, Denmark, Sweden, England, Ireland, Belgium, and Lithuania
Autor: | E. Van Eycken, Sarah Lawton, Lene Hjerrild Iversen, T. Evans, R. Janciauskiene, Petra G. Boelens, Esther Bastiaannet, Robert Johansson, Andrés Cervantes, Valery E.P.P. Lemmens, G.J. Liefers, Anna Martling, A.J. Breugom, Katie M O'Brien, C.J.H. van de Velde |
---|---|
Přispěvatelé: | Public Health |
Rok vydání: | 2016 |
Předmět: |
0301 basic medicine
Adult Male Cancer Research medicine.medical_specialty Adjuvant chemotherapy Colorectal cancer Population Disease Population-based Stage II 03 medical and health sciences 0302 clinical medicine Pharmacotherapy SDG 3 - Good Health and Well-being Internal medicine Antineoplastic Combined Chemotherapy Protocols Journal Article medicine Humans Stage (cooking) education International comparison Aged Gynecology education.field_of_study Relative survival business.industry Research Support Non-U.S. Gov't Middle Aged medicine.disease Survival Analysis Colon cancer Europe 030104 developmental biology Logistic Models Oncology Chemotherapy Adjuvant 030220 oncology & carcinogenesis Colonic Neoplasms Surgery Female business Stage ii colon cancer |
Zdroj: | Breugom, A J, Bastiaannet, E, Boelens, P G, Iversen, L H, Martling, A, Johansson, R, Evans, T, Lawton, S, O'Brien, K M, Van Eycken, E, Janciauskiene, R, Liefers, G J, Cervantes, A, Lemmens, V E P P & van de Velde, C J H 2016, ' Adjuvant chemotherapy and relative survival of patients with stage II colon cancer-A EURECCA international comparison between the Netherlands, Denmark, Sweden, England, Ireland, Belgium, and Lithuania ', European journal of cancer (Oxford, England : 1990), vol. 63, pp. 110-7 . https://doi.org/10.1016/j.ejca.2016.04.017 European Journal of Cancer, 63, 110-117. Elsevier Ltd. European Journal of Cancer, 63, 110-117 |
ISSN: | 1879-0852 0959-8049 |
Popis: | BACKGROUND: The aim of the present EURECCA international comparison is to compare adjuvant chemotherapy and relative survival of patients with stage II colon cancer between European countries.METHODS: Population-based national cohort data (2004-2009) from the Netherlands (NL), Denmark (DK), Sweden (SE), England (ENG), Ireland (IE), and Belgium (BE) were obtained, as well as single-centre data from Lithuania. All surgically treated patients with stage II colon cancer were included. The proportion of patients receiving adjuvant chemotherapy was calculated and compared between countries. Besides, relative survival was calculated and compared between countries.RESULTS: Overall, 59,154 patients were included. The proportion of patients receiving adjuvant chemotherapy ranged from 7.1% to 29.0% (p < 0.001). Compared with NL, a better adjusted relative survival was observed in SE (stage II: relative excess risks (RER) 0.53, 95% confidence interval (CI) 0.44-0.64; p < 0.001), and BE (stage II: RER 0.84, 95% CI 0.76-0.92; p < 0.001), and in IE for patients with stage IIA disease (RER 0.80, 95% CI 0.65-0.98; p = 0.03).CONCLUSION: The proportion of patients with stage II colon cancer receiving adjuvant chemotherapy varied largely between seven European countries. No clear linear pattern between adjuvant chemotherapy and adjusted relative survival was observed. Compared with NL, SE and BE showed an improved adjusted relative survival for stage II disease, and IE for patients with stage IIA disease only. Further research into selection criteria for adjuvant chemotherapy could eventually lead to individually tailored, optimal treatment of patients with stage II colon cancer. |
Databáze: | OpenAIRE |
Externí odkaz: |